Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptivus Limited Part D Formulary Coverage May Reflect Approval Timing

Executive Summary

Boehringer Ingelheim's experience with Part D placement for its HIV therapy Aptivus points to the importance of approval timing in securing formulary coverage on Medicare drug plans

You may also be interested in...



Branded Antidepressants Face Challenges With Part D Formulary Positions

The Centers for Medicare & Medicaid Services appears to be interpreting its "all or substantially all" policy for Part D plan coverage of antidepressants as allowing sponsors to include the majority of agents on high cost-sharing tiers, according to analysis of plan formularies conducted by "The Pink Sheet."

Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study

Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)

Medicare Part D Formularies May Omit Lexapro Or Celexa, CMS Says

Medicare Part D plans will not be required to include both Forest antidepressants Lexapro and Celexa in their formularies, the Centers for Medicare & Medicaid Services said in a supplement to a question and answer document on the program

Related Content

UsernamePublicRestriction

Register

PS046876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel